Daiichi Sankyo

Daiichi Sankyo
Daiichi Sankyo Co., Ltd.
Type Public KK (TYO: 4568)
Industry Pharmaceutical
Founded 2005 (by merger)
Headquarters Tokyo, Japan
Key people Takashi Shoda, Chairman
Joji Nakayama, President & CEO

increase $11.655 billion USD

(¥ 967.4 billion JPY) (FY 2010)
Net income increase ¥ 131,800 million JPY (FY 2010)

30,488 (2010)

products = Pharmaceutical products
Website www.daiichisankyo.com

Daiichi Sankyo Co., Ltd. (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?, TYO: 4568) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 970 billion in revenue in 2010 and is currently ranked number 17 in world sales. Its headquarter is based in Tokyo. The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India. Daiichi Sankyo is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. with total sales of USD 2.7 billion.

Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.

Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.

Daiichi Sankyo Co., Ltd. is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).



Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社 Sankyō Kabushiki Kaisha?) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha?), which were century-old pharmaceutical companies based in Japan.


In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.[1][2]

In June 2008, Daiichi Sankyo acquired U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.[3]

On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkley CA-based pharmaceutical start-up company for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug. [4]

Products of Daiichi Sankyo Group


Daiichi Pharmaceutical

Pipeline candidates

Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:

  • CS-011 (rivoglitazone)—Type 2 Diabetes
  • CS-1008—Oncology
  • CS-8958 (Laninamivir)—Influenza
  • DU-176b—Venous thromboembolism
  • SUN-11031—Cachexia


External links